PRIMA-SOLUTIONS
As part of its continuing growth strategy, Prima Solutions (Prima), the premier software platform for Property and Casualty insurers, has agreed to acquire ICOD Inc. (ICOD), the Canadian provider of software solutions for Life and Health insurance. Recognized as an established leader with its SN Assurance suite, ICOD offers a best-in class solution deliverable in SaaS or on premise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005019/en/
The transaction, which closed on September 20th, accelerates Prima’s expansion into the Life and Health insurance market which is still largely using legacy technologies. The ICOD acquisition offers many synergies including: complementing Prima’s existing product offering, diversifying its customer base and expanding the platform for rapid growth in both Europe and North America.
Hugues Delannoy, Chairman of Prima Solutions, said: "This acquisition provides a unique opportunity to accelerate our growth strategy and gain scale both in France and internationally. The transaction offers immediate synergies and reinforces our plan to diversify our product offering to take advantage of the fast growing demand in the Life and Health insurance segment for a modern scalable platform .”
Pascal Gosset, Founding President of ICOD Inc., added: "Having already worked closely together with Prima on several occasions, our shared vision has led us to join forces to position ourselves as one of the strategic technology providers in the Property and Casualty and the Life and Health insurance markets. The combination of both organizations will allow clients continue to benefit from the same high level of quality service and expertise while also gaining access to increased product offerings through a single software provider ".
About Prima Solutions
Prima Solutions provides Property and
Casualty insurers the cutting-edge Prima Insure™ software platform to
increase agility and become a leader in insurance innovation. 100
percent web enabled, modular, multilingual and delivered via SaaS mode,
Prima Insure™ addresses the entire life cycle of an insurance policy:
distribution; underwriting; contract; claims, financial management and
predictive analytics. More than 67 Property and Casualty insurers have
already chosen to innovate with Prima Insure™. Prima Solutions is a
member of ACORD.
Web
www.prima-solutions.com
| Twitter
https://twitter.com/Prima_Solutions
About ICOD
Founded in 2000 in Montreal ICOD delivers the
software platform Life and Health insurers need to gain in agility and
efficiency in a highly competitive market. Full web, modular,
multilingual and available in SaaS mode, ICOD’s software platform
addresses the whole life cycle of an insurance policy: distribution;
underwriting; contract management; claims and financial management. More
than 10 Life and Health insurers have selected ICOD’s software platform
to manage their activities end-to-end. ICOD employs 55 professionals
worldwide, and its employees will become part of the Prima Solutions
group in the context of this transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005019/en/
Contact:
MEDIA Prima Solutions Frédéric DUTREUIL, +33(0)1-70-91-13-16 / +33(0)6-24-04-23-39 frederic.dutreuil@prima-solutions.com or Leslie MADUBOST, +33(0)1-70-91-24-78 leslie.madubost@prima-solutions.com or Steele&Holt Daphne CLAUDE & Dominic RIDING, +33(0)6-66-58-81-92 / +33(0)6-57-48-83-24 carlyle@steeleandholt.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom